Quizartinib for the treatment of acute myeloid leukemia

References

• Estey E, Döhner H. Acute myeloid leukaemia. Lancet. 2006;368(9550):1894–1907.
   PubMed Web of Science ®Google Scholar
• SEER NCI-. Cancer stat facts: leukemia - acute myeloid leukemia (AML). [cited 2020 Jan 9]. Available from: https://seer.cancer.gov/statfacts/html/amyl.html.
   Google Scholar
• Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909–1918.
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–2074.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221.
   PubMed Web of Science ®Google Scholar
• Smith CC. The growing landscape of FLT3 inhibition in AML. Hematology. 2019;2019(1):539–547.
   PubMedGoogle Scholar
• Adolfsson J, Månsson R, Buza-Vidas N, et al. Identification of Flt3+ lympho-myeloid stem cells lacking Erythro-Megakaryocytic potential: a revised road map for adult blood lineage commitment. Cell. 2005;121(2):295–306.
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Kantarjian H, Ravandi F, et al. FLT3 inhibitors in the treatment of acute myeloid leukemia. Cancer. 2011;117(15):3293–3304.
   PubMed Web of Science ®Google Scholar
• Perl AE. Availability of FLT3 inhibitors: how do we use them? Blood. 2019;134(9):741–745.
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom medical research council AML 10 and 12 trials. Blood. 2001;98(6):1752–1759.
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Kayser S, Bullinger L, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood. 2014;124(23):3441–3449.
   PubMed Web of Science ®Google Scholar
• Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100(1):59–66.
   PubMed Web of Science ®Google Scholar
• Linch DC, Hills RK, Burnett AK, et al. Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. Blood. 2014;124(2):273–276.
   PubMed Web of Science ®Google Scholar
• How J, Sykes J, Gupta V, et al. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia. Cancer. 2012;118(24):6110–6117.
   PubMed Web of Science ®Google Scholar
• Stirewalt DL, Kopecky KJ, Meshinchi S, et al. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood. 2006;107(9):3724–3726.
   PubMed Web of Science ®Google Scholar
• Liu SB, Dong HJ, Bao XB, et al. Impact of FLT3-ITD length on prognosis of acute myeloid leukemia. Haematologica. 2019;104(1):e9–e12.
   PubMed Web of Science ®Google Scholar
• Kayser S, Schlenk RF, Londono MC, et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood. 2009;114(12):2386–2392.
   PubMed Web of Science ®Google Scholar
• Dohner K, Thiede C, Jahn N, et al. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood. 2020;135(5):371–380.
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Gale RE, Langabeer SE, et al. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood. 2002;100(7):2393–2398.
   PubMed Web of Science ®Google Scholar
• Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481(7382):506–510.
   PubMed Web of Science ®Google Scholar
• Nazha A, Cortes J, Faderl S, et al. Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica. 2012;97(8):1242–1245.
   PubMed Web of Science ®Google Scholar
• Ottone T, Zaza S, Divona M, et al. Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin. Br J Haematol. 2013;161(4):533–540.
   PubMed Web of Science ®Google Scholar
• Daver N, Schlenk RF, Russell NH, et al. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299–312.
   PubMed Web of Science ®Google Scholar
• Griffith J, Black J, Faerman C, et al. The structural basis for Autoinhibition of FLT3 by the Juxtamembrane domain. Mol Cell. 2004;13(2):169–178.
   PubMed Web of Science ®Google Scholar
• Zorn JA, Wang Q, Fujimura E, et al. Crystal structure of the FLT3 Kinase domain bound to the inhibitor Quizartinib (AC220). Plos One. 2015;10(4):e0121177.
   PubMed Web of Science ®Google Scholar
• Verstraete K, Vandriessche G, Januar M, et al. Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex. Blood. 2011;118(1):60–68.
   PubMed Web of Science ®Google Scholar
• Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000;19(5):624–631.
   PubMed Web of Science ®Google Scholar
• Mizuki M, Fenski R, Halfter H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 2000;96(12):3907–3914.
   PubMed Web of Science ®Google Scholar
• Parcells BW, Ikeda AK, Simms-Waldrip T, et al. 3 in normal hematopoiesis and acute myeloid leukemia. Stem Cells. 2006;24(5):1174–1184.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5(10):835–844.
   PubMed Web of Science ®Google Scholar
• Kane RC, Farrell AT, Saber H, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res. 2006;12(24):7271–7278.
   PubMed Web of Science ®Google Scholar
• Kane RC, Farrell AT, Madabushi R, et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist. 2009;14(1):95–100.
   PubMed Web of Science ®Google Scholar
• Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319–328.
   PubMed Web of Science ®Google Scholar
• Delmonte J, Kantarjian HM, Andreeff M, et al. Update of a phase I study of sorafenib in patients with refractory/relapsed acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood. 2007;110(11):893.
   Web of Science ®Google Scholar
• Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood. 2009;113(26):6567–6571.
   PubMed Web of Science ®Google Scholar
• Metzelder SK, Schroeder T, Lubbert M, et al. Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. Eur J Cancer. 2017;86:233–239.
   PubMed Web of Science ®Google Scholar
• Rollig C, Serve H, Huttmann A, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16(16):1691–1699.
   PubMed Web of Science ®Google Scholar
• Serve H, Krug U, Wagner R, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol. 2013;31(25):3110–3118.
   PubMed Web of Science ®Google Scholar
• Ohanian M, Garcia-Manero G, Levis M, et al. Sorafenib combined with 5-azacytidine in older patients with untreated FLT3-ITD mutated acute myeloid leukemia. Am J Hematol. 2018;93(9):1136–1141.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Alattar ML, Grunwald MR, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013;121(23):4655–4662.
   PubMed Web of Science ®Google Scholar
• Burchert A, Bug G, Finke J, et al. Sorafenib as maintenance therapy post Allogeneic stem cell transplantation for FLT3-ITD positive AML: results from the randomized, double-blind, placebo-controlled multicentre Sormain trial. Blood. 2018;132(Supplement 1):661.
   Google Scholar
• Levis MJ, Chen YB, Hamadani M, et al. FLT3 inhibitor maintenance after Allogeneic transplantation: is a placebo-controlled, randomized trial ethical? J Clin Oncol. 2019;37(19):1604–1607.
   PubMed Web of Science ®Google Scholar
• Fabbro D, Buchdunger E, Wood J, et al. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Ther. 1999;82(2–3):293–301.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002;1(5):433–443.
   PubMed Web of Science ®Google Scholar
• Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105(1):54–60.
   PubMed Web of Science ®Google Scholar
• Fischer T, Stone RM, Deangelo DJ, et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol. 2010;28(28):4339–4345.
   PubMed Web of Science ®Google Scholar
• Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–464.
   PubMed Web of Science ®Google Scholar
• RYDAPT. (Midostaurin) prescribing information. [cited 2020 Jan 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf.
   Google Scholar
• Larson RA, Mandrekar SJ, Sanford BL, et al. An analysis of maintenance therapy and post-midostaurin outcomes in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603/RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations. Blood. 2017;130:145.
   Web of Science ®Google Scholar
• Lee LY, Hernandez D, Rajkhowa T, et al. Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood. 2017;129(2):257–260.
   PubMed Web of Science ®Google Scholar
• Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–1740.
   PubMed Web of Science ®Google Scholar
• XOSPATA. (Gilteritinib) prescribing information. [cited 2020 Jan 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf.
   Google Scholar
• Smith CC, Levis MJ, Perl AE, et al. Emerging mutations at relapse in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia who received gilteritinib therapy in the phase 3 admiral trial. Blood. 2019;134:14.
   Web of Science ®Google Scholar
• McMahon CM, Ferng T, Canaani J, et al. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. 2019;9(8):1050–1063.
   PubMed Web of Science ®Google Scholar
• Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017;18(8):1061–1075.
   PubMed Web of Science ®Google Scholar
• Tzogani K, Roshol H, Olsen HH, et al. The European Medicines Agency review of gilteritinib (Xospata) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an FLT3 mutation. Oncologist. 2020;25(7):e1070–e1076.
   Web of Science ®Google Scholar
• Perl AE, Daver NG, Pratz KW, et al. Venetoclax in combination with gilteritinib in patients with relapsed/refractory acute meloid leukemia: a phase 1b study. Blood. 2019;134:3910.
   Web of Science ®Google Scholar
• Galanis A, Ma H, Rajkhowa T, et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood. 2014;123(1):94–100.
   PubMed Web of Science ®Google Scholar
• Smith CC, Lasater EA, Lin KC, et al. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci U S A. 2014;111(14):5319–5324.
   PubMed Web of Science ®Google Scholar
• Zhang H, Savage S, Schultz AR, et al. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nat Commun. 2019;10(1):244.
   PubMedGoogle Scholar
• Wang ES, Griffiths EA, Walter RB, et al. Tolerability and efficacy of crenolanib and cytarabine/anthracycline chemotherapy in older patients (aged 61 to 75) with newly diagnosed FLT3-mutated acute myeloid leukemia (AML). Blood. 2019;134:3829.
   Web of Science ®Google Scholar
• Goldberg AD, Coombs CC, Wang ES, et al. Younger patients with newly diagnosed FLT3-mutant AML treated with crenolanib plus chemotherapy achieve adequate free crenolanib levels and durable remissions. Blood. 2019;134:1326.
   Web of Science ®Google Scholar
• Oran B, O. CS, Marin D, et al. Safety analysis of intra-patient dose - study of crenolanib maintenance therapy in patients with FLT3 mutant AML following allogeneic hematopoietic stem cell transplant. Blood. 2018;132:3426.
   Web of Science ®Google Scholar
• Zarrinkar PP, Gunawardane RN, Cramer MD, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009;114(14):2984–2992.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3–internal tandem duplication status. J Clin Oncol. 2013;31(29):3681–3687.
   PubMed Web of Science ®Google Scholar
• Chao Q, Sprankle KG, Grotzfeld RM, et al. Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like Tyrosine Kinase-3 (FLT3) inhibitor. J Med Chem. 2009;52(23):7808–7816.
   PubMed Web of Science ®Google Scholar
• National Center for Biotechnology Information. PubChem database. Quizartinib. n.d. [2020 Jan 9]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Quizartinib.
   Google Scholar
• Smith CC, Lin K, Stecula A, et al. FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors. Leukemia. 2015;29(12):2390–2392.
   PubMed Web of Science ®Google Scholar
• Sexauer A, Perl A, Yang X, et al. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood. 2012;120(20):4205–4214.
   PubMed Web of Science ®Google Scholar
• Ke YY, Singh VK, Coumar MS, et al. Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification. Sci Rep. 2015;5:11702.
   PubMed Web of Science ®Google Scholar
• Sanga M, James J, Marini J, et al. An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia. Xenobiotica. 2017;47(10):856–869.
   PubMed Web of Science ®Google Scholar
• Li J, Holmes M, Kankam M, et al. Effect of food on the pharmacokinetics of Quizartinib. Clin Pharmacol Drug Dev. 2020;9(2):277–286.
   PubMed Web of Science ®Google Scholar
• James J, Pratz K, Stine A, et al. Clinical pharmacokinetics and FLT3 phosphorylation of AC220, a highly potent and selective inhibitor of FLT3. Blood. 2008;112(11):2637.
   Web of Science ®Google Scholar
• Usuki K, Handa H, Choi I, et al. Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study. Int J Hematol. 2019;110(6):654–664.
   PubMed Web of Science ®Google Scholar
• Li J, Kankam M, Trone D, et al. Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite. Br J Clin Pharmacol. 2019;85(9):2108–2117.
   PubMed Web of Science ®Google Scholar
• Li J, Trone D, Mendell J, et al. A drug–drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics. Cancer Chemother Pharmacol. 2019;84(4):799–807.
   PubMed Web of Science ®Google Scholar
• Smith CC, Wang Q, Chin C-S, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012;485(7397):260–263.
   PubMed Web of Science ®Google Scholar
• Smith CC, Zhang C, Lin KC, et al. Characterizing and overriding the structural mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L mutation with PLX3397. Cancer Discov. 2015;5(6):668–679.
   PubMed Web of Science ®Google Scholar
• Naqvi K, Ravandi F. FLT3 inhibitor quizartinib (AC220). Leuk Lymphoma. 2019;60(8):1866–1876.
   PubMed Web of Science ®Google Scholar
• Yang X, Sexauer A, Levis M. Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase. Br J Haematol. 2014;164(1):61–72.
   PubMed Web of Science ®Google Scholar
• Parmar A, Marz S, Rushton S, et al. Stromal Niche cells protect early Leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 Tyrosine Kinase inhibitors. Cancer Res. 2011;71(13):4696–4706.
   PubMed Web of Science ®Google Scholar
• Sato T, Yang X, Knapper S, et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood. 2011;117(12):3286–3293.
   PubMed Web of Science ®Google Scholar
• Cortes J, Perl AE, Döhner H, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018;19(7):889–903.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Tallman MS, Schiller GJ, et al. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML. Blood. 2018;132(6):598–607.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):984–997.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Ganguly S, Khaled SK, et al. Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of quizartinib vs salvage chemotherapy in patients with relapsed/refractory (R/R) FLT3-ITD acute myeloid leukemia (AML). Blood. 2019;134:382.
   Web of Science ®Google Scholar
• Takahashi T, Usuki K, Matsue K, et al. Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study. Int J Hematol. 2019;110(6):665–674.
   Web of Science ®Google Scholar
• Altman JK, Foran JM, Pratz KW, et al. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2018;93(2):213–221.
   PubMed Web of Science ®Google Scholar
• Abdelall W, Kantarjian HM, Borthakur G, et al. The combination of Quizartinib with Azacitidine or low dose Cytarabine is highly active in patients (Pts) with FLT3-ITD mutated myeloid leukemias: interim report of a phase I/II trial. Blood. 2016;128(22):1642.
   PubMed Web of Science ®Google Scholar
• Swaminathan M, Kantarjian HM, Daver N, et al. The combination of Quizartinib with Azacitidine or low dose Cytarabine is highly active in patients (Pts) with FLT3-ITD mutated myeloid leukemias: interim report of a phase I/II trial. Blood. 2017;130(Supplement 1):723.
   Google Scholar
• Zhang C, Leung GMK, Tsui SP, et al. A phase II single-arm open-labeled study evaluating combination of quizartinib and omacetaxine mepesuccinate (QUIZOM) in newly diagnosed or relapsed/refractory AML carrying FlT3-ITD. Blood. 2019;134:3825.
   Web of Science ®Google Scholar
• Sandmaier BM, Khaled S, Oran B, et al. Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant. Am J Hematol. 2018;93(2):222–231.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Ganguly S, Krämer A, et al. Pooled Safety analysis of Quizartinib monotherapy in patients with relapsed/ refractory (R/R) acute myeloid leukemia (AML). Blood. 2019;134(Supplement_1):1372.
   Google Scholar
• Galanis A, Levis M. Inhibition of c-Kit by tyrosine kinase inhibitors. Haematologica. 2015;100(3):e77–e9.
   PubMed Web of Science ®Google Scholar
• Daiichi-Sankyo. Daiichi Sankyo’s VANFLYTA® receives approval in Japan for the treatment of relapsed/refractory FLT3-ITD AML 2019. [2020 Jan 20]. Available from: https://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/007030.html.
   Google Scholar